Pfizer Inc.

PFE Healthcare Drug Manufacturers General

Pfizer Inc.’s revenue for fiscal 2025 (year ended December 2025) was $62.6 billion, down 1.65% from fiscal 2024.

Revenue
−0.43%
EPS
−7.98%
Free cash flow
+20.0%
Total debt
+1.55%

Quarter to September 2026, against a year earlier

29.96 0.83 −2.70%
Market cap
$170.3B
P/E
42.2×
Fwd P/E
18.9×
Dividend yield
7.18%
F-score
6/9
Altman Z
2.03
Beneish M
−2.52
Dividend safety
28/100

Pfizer Inc. (PFE) P/E ratio

Alert me on P/E ratio

As of 5 November 2026, Pfizer Inc. (PFE) trades at a P/E ratio of 42.2×. Over the past ten years it has ranged from 0.0× (September 2024) to 82.6× (January 2024); the current reading is higher than 98% of that period. That is above the Drug Manufacturers General industry median of 26.6× and above the Healthcare sector median of 25.2×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 18.3× (2.11%)
FY2024 18.7× (77.35%)
FY2023 82.6× 797.36%
FY2022 9.2× (39.22%)
FY2021 15.1× (29.25%)
FY2020 21.4× 62.60%
FY2019 13.2× (42.01%)
FY2018 22.7× 127.48%
FY2017 10.0× (63.81%)
FY2016 27.6× 13.42%

Quarterly newest first

Period P/E ratio Change
Sep 2026 40.1× 26.69%
Jun 2026 31.7× 47.81%
Mar 2026 21.4× 17.08%
Dec 2025 18.3× 23.59%
43 more quarters

Against its own ten years

Low 0.0× High 82.6×
Ten-year median 18.5×
Current reading's percentile 97

P/E ratio against peers

Company P/E ratio
GILD Gilead Sciences, Inc. compare n/m
NVO Novo Nordisk A/S compare 9.9×
BMY Bristol Myers Squibb Company compare 14.0×
GSK GSK PLC Sponsored ADR compare 16.7×
SNY Sanofi compare 23.2×
AZN AstraZeneca PLC compare 26.3×
AMGN Amgen Inc. compare 26.6×
NVS Novartis AG compare 30.9×
PFE Pfizer Inc. 42.2×
Drug Manufacturers General industry median 26.6×
Healthcare sector median 25.2×
Market median 17.9×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on PFE